Cost of Revenue Comparison: Amgen Inc. vs Exelixis, Inc.

Cost of Revenue: Amgen Inc. vs. Exelixis, Inc.

In the competitive landscape of biotechnology, understanding cost efficiency is crucial. Over the past decade, Amgen Inc. and Exelixis, Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Amgen's cost of revenue surged by approximately 90%, reflecting its expansive operations and market reach. In contrast, Exelixis, Inc. experienced a staggering increase of over 3,400% in the same period, albeit from a much smaller base, highlighting its rapid growth phase.

Key Insights

• Amgen Inc.: Despite a consistent rise, Amgen's cost of revenue remained relatively stable until 2019, after which it saw a significant jump, peaking in 2023.
• Exelixis, Inc.: Starting from a modest base, Exelixis's cost of revenue grew exponentially, indicating aggressive scaling and investment in its operations.

These trends underscore the dynamic nature of the biotech industry, where strategic investments and scaling can lead to vastly different financial outcomes.